Related Experiment Video

Updated: Jun 27, 2026

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Development of PARP inhibitors in oncology

Jordi Rodon1, Maria D Iniesta, Kyriakos Papadopoulos

  • 1UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, (Unit 455), 1515 Holcombe Blvd, Houston, TX 77030, USA. jrodonahnert@gmail.com

Expert Opinion on Investigational Drugs
|December 5, 2008
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for DNA repair-defective cancers. Combining PARP inhibition with chemotherapy or radiation may enhance treatment efficacy, with ongoing clinical trials exploring biomarkers and therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase (PARP) is crucial for DNA repair pathways.
  • PARP inhibition in tumors with DNA repair defects (e.g., BRCA1/2 mutations) induces genomic instability and cell death.
  • Preclinical models demonstrate synergistic effects of combining PARP inhibitors with cytotoxic agents like chemotherapy and radiation therapy.

Purpose of the Study:

  • To review early clinical data on PARP inhibitors.
  • To identify potential tumor targets for PARP inhibitors.
  • To discuss combination therapies, biomarkers, and novel development concepts for PARP inhibitors.

Main Methods:

  • Review of early clinical trial data for PARP inhibitors.
  • Discussion of preclinical synergistic findings.
  • Exploration of biomarkers and development strategies.

Main Results:

  • Several PARP inhibitors are in clinical development with unique therapeutic pathways.
  • Combination therapies with cytotoxic agents show synergistic potential.
  • Biomarkers and concepts like 'BRCAness' and synthetic lethality are key to development.

Conclusions:

  • PARP inhibitors represent a promising class of anticancer agents, particularly for DNA repair-defective tumors.
  • The development of PARP inhibitors involves novel strategies, including combination therapies and biomarker-driven approaches.
  • Further clinical investigation is essential to optimize the use of PARP inhibitors in cancer treatment.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...